NCT06284772

FINRISK 2002 Re-examination

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,500 (actual)
• Sponsor: University of Turku · Academic / Other
• Sex: All
• Age: 47 Years – 96 Years
• Healthy volunteers: Accepted

Summary

The project aims to fill in the existing gaps in the study of the microbiome as a cardiometabolic driver 1) by determining the key demographic, environmental, genetic, dietary, and metabolic correlates of long-term within-individual microbiome and microbial metabolite changes; and 2) by assessing how the gut microbiome, microbial metabolites, and their long-term changes are prospectively related to the risk factors, surrogate markers, and overt outcomes of CMD. To achieve this goal, repeat stool samples will be collected of \~2300 Finnish individuals who gave stool samples in the year 2002. In addition, \~300 individuals will undergo a in-depth health examination in 2024.

Conditions

• Cardiometabolic Syndrome
• Cardiovascular Diseases

Interventions

Type	Name	Description
OTHER	Questionnaire and fecal sampling	The participants will be mailed a fecal collection kit and a 20-page health questionnaire. This questionnaire will include the similar questions concerning health, lifestyles, and diet as in 2002.
OTHER	Health examination	This examination will include measurements for anthropometrics, cognition (MoCA, Stroop, DSST), and blood pressure. The participants will undergo blood draw for laboratory analyses of CMD risk factors, such as blood lipids, glucose metabolism (fasting glucose, HbA1c, and fasting insulin), liver enzymes (GGT, ALT, and AST), inflammation (hs-CRP), and cardiac markers (proBNP and hs-TnI). We will perform ultrasound imaging for hepatic fibrosis.

Timeline

• Start date: 2023-11-13
• Primary completion: 2024-06-25
• Completion: 2024-06-25
• First posted: 2024-02-29
• Last updated: 2024-12-09

Locations

1 site across 1 country: Finland